150 related articles for article (PubMed ID: 31530886)
1. Reductions in LDL-cholesterol and blood-pressure levels have cumulative benefits.
Lim GB
Nat Rev Cardiol; 2019 Nov; 16(11):650. PubMed ID: 31530886
[No Abstract] [Full Text] [Related]
2. LDL Cholesterol and Cardiovascular Events in a Population Network: One More Twist of an Endless Story.
Minotti G; Camilli M
J Pharmacol Exp Ther; 2024 Feb; 388(3):739-741. PubMed ID: 38360802
[No Abstract] [Full Text] [Related]
3. Review: More-intensive vs less-intensive LDL-cholesterol lowering reduces mortality.
Yeboah J
Ann Intern Med; 2018 Jul; 169(2):JC6. PubMed ID: 30014095
[No Abstract] [Full Text] [Related]
4. Low-density lipoprotein cholesterol: how low can we go?
Sherbet DP; Garg P; Brilakis ES; Banerjee S
Am J Cardiovasc Drugs; 2013 Aug; 13(4):225-32. PubMed ID: 23609530
[TBL] [Abstract][Full Text] [Related]
5. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
Sniderman AD; Thanassoulis G
Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
[No Abstract] [Full Text] [Related]
6. Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM; Lam KS
Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
[No Abstract] [Full Text] [Related]
7. Lowering LDL cholesterol is good, but how and in whom?
Stone NJ; Lloyd-Jones DM
N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
[No Abstract] [Full Text] [Related]
8. Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease.
Stein EA
Mayo Clin Proc; 2009 Apr; 84(4):307-9. PubMed ID: 19339646
[No Abstract] [Full Text] [Related]
9. Lipid parameters and cardiovascular events in patients taking statins.
Brook RD; Rubenfire M
JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
[No Abstract] [Full Text] [Related]
10. Lipid parameters and cardiovascular events in patients taking statins.
Martin SS; Jones SR
JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
[No Abstract] [Full Text] [Related]
11. Pooled RCTs: Lowering LDL-C levels using statins reduces major vascular events in all age groups.
Lee J; Holbrook A
Ann Intern Med; 2019 Jun; 170(12):JC65. PubMed ID: 31207618
[No Abstract] [Full Text] [Related]
12. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
Olsson AG
Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
[No Abstract] [Full Text] [Related]
13. PCSK9 Inhibitors and Cardiovascular Events.
Sabatine MS; Wasserman SM; Stein EA
N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
[No Abstract] [Full Text] [Related]
14. PCSK9 Inhibitors and Cardiovascular Events.
Goemann IM; Londero TM; Dora JM
N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
[No Abstract] [Full Text] [Related]
15. PCSK9 Inhibitors and Cardiovascular Events.
Auer J; Berent R; Primus C
N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
[No Abstract] [Full Text] [Related]
16. PCSK9 Inhibitors and Cardiovascular Events.
Robinson JG; Kastelein JJ
N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
[No Abstract] [Full Text] [Related]
17. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
Mayor S
BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
[No Abstract] [Full Text] [Related]
18. Further LDL Lowering Could Reduce Cardiovascular Risk.
Mechcatie E; Rosenberg K
Am J Nurs; 2018 Nov; 118(11):55-56. PubMed ID: 30358599
[TBL] [Abstract][Full Text] [Related]
19. When economy meets physiopathology: A novel cost-effectiveness model finally considers the cumulative effect of LDL cholesterol burden.
Carvalho LSF; Stephanus AD; Pfitzner MS
Atherosclerosis; 2023 Feb; 367():34-36. PubMed ID: 36725420
[No Abstract] [Full Text] [Related]
20. Placing PRINCE in perspective.
Simpson RJ
JAMA; 2001 Jul; 286(1):91-3. PubMed ID: 11434833
[No Abstract] [Full Text] [Related]
[Next] [New Search]
